US8110331092
US8110331092
Scribe Therapeutics Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 |
|---|---|---|
Market & Enterprise Value | ||
Market Cap | 400.78M EUR | -- |
Enterprise Value | 484.67M EUR | -- |
Valuation Multiples | ||
Trailing P/E | -- | -- |
Forward P/E | -5.85x | -- |
Price to Sales | 12.03x | -- |
Price to Book | -- | -- |
EV/Revenue | 14.55x | -- |
EV/EBITDA | -17.42x | -- |
Price to FCF (P/FCF) | -- | -- |
EV/FCF | -- | -- |
FCF Yield | -- | -- |